From PDFs to Structured Data: Understanding EMA’s DADI Project

The European Medicines Agency (EMA) is at the forefront of digital transformation in pharmaceutical regulation through its Digital Application Dataset Integration (DADI) project. This initiative marks a significant departure from traditional document-based submissions and evolving into structured, data-driven regulatory processes. By leveraging modern data standards and digital technologies, DADI aims to streamline regulatory workflows, enhance data quality, and improve the efficiency of medicinal product assessments across the European Union. 

Overview of Regulatory Submissions 

Understanding Regulatory Submissions 

Regulatory submissions are crucial for gaining approval to market a pharmaceutical product. These submissions provide comprehensive data on a product’s safety, efficacy, and manufacturing processes. 

Historically, the electronic Common Technical Document (eCTD) has been the standard format for such submissions. However, eCTD relies heavily on static PDFs and manual data entry, which can introduce inefficiencies and errors. 

Instead of relying on static documents, DADI introduces web-based electronic application forms (eAFs) that use structured data. These forms are hosted on the Product Lifecycle Management (PLM) Portal, allowing for integration with EMA databases, and improved data use across regulatory systems. 

Importance of Data-Based Submissions 

Transitioning to structured, data-based submissions offers numerous advantages. First and foremost, it enhances the accuracy and consistency of regulatory data, reducing the risk of discrepancies that can delay approvals. Structured data also enables automated validation, ensuring that submissions meet regulatory requirements before they are even reviewed. 

Moreover, this approach facilitates faster and more informed decision-making by regulatory authorities. With data that is machine-readable and interoperable, agencies can perform advanced analytics, identify trends, and respond more quickly to emerging safety concerns. This not only benefits regulators but also accelerates the availability of safe and effective treatments for patients. 

The DADI Project and Its Impact 

Key Components of the DADI Project 

The primary objective of the DADI project is to streamline regulatory processes for medicinal product assessment and approval. This encompasses several key improvements, including: 

• Use of FHIR (Fast Healthcare Interoperability Resources) and ISO IDMP (Identification of Medicinal Products) standards to ensure that data is structured, standardized, and interoperable across systems. 

• Integration with EMA’s SPOR (Substance, Product, Organisation, Referential) and PMS (Product Management Service) databases, enabling automatic population of form fields and reducing manual input. 

• Improving regulatory intelligence gathering and analysis, enabling regulatory authorities to make more informed decisions regarding the safety and efficacy of pharmaceutical products. 

The project began with variation forms for human medicines and is gradually expanding to cover all types of regulatory submissions. A transition period allowed for parallel use of PDF and web-based forms, but full adoption is expected soon. A number of questions have been asked about DADI since its inception, and an official Q&A has been released by the EMA. 

Benefits for Regulatory Agencies 

The DADI project offers several benefits for regulatory agencies such as the EMA. By transitioning to data-based regulatory submissions, regulatory agencies can significantly enhance efficiency. This leads to several advantages: 

• For regulatory agencies like the EMA, it means faster access to high-quality data, improved collaboration across EU member states, and enhanced transparency. 

• For pharmaceutical companies, it reduces administrative burden, minimizes compliance risks, and supports more agile regulatory strategies. 

This update also supports lifecycle management of medicinal products. From development through post-market surveillance, structured data allows for efficient tracking of changes, rapid updates, and continuous compliance with evolving regulations. 

Dynamic Regulatory Submissions in the Pharmaceutical Industry 

Adapting to Changes in the Regulatory Landscape 

The regulatory environment is constantly evolving, driven by scientific advancements, public health needs, and global harmonization efforts. The DADI project equips both regulators and industry stakeholders with the tools to adapt quickly. 

One strategy for pharmaceutical companies to adopt to these new updates is to use regulatory information management systems (RIMS) and structured content platforms to stay compliant and competitive. These platforms serve as the digital backbone for managing regulatory activities across the product lifecycle, letting their clients track regulatory requirements across multiple markets and jurisdictions, manage submission timelines, documents, and correspondence in a centralized system and ensure data consistency across all regulatory filings and product variations. 

By integrating a RIM system with other enterprise systems, such as Quality Management Systems (QMS), Document Management Systems (DMS), and Product Lifecycle Management (PLM) tools, RIMS platforms provide a single source of truth for regulatory data, which can be especially useful in the context of structured data submissions like those required by DADI. 

Future Trends in Regulatory Submissions 

The DADI project is just the beginning. As digital transformation continues, expect to see further integration of AI-assisted reviews, system-to-system data exchange, and global regulatory harmonization. The use of structured data will become the norm, not the exception, enabling a more responsive, efficient, and transparent regulatory ecosystem.